42.60
1.11 (2.68%)
| Previous Close | 41.49 |
| Open | 41.70 |
| Volume | 510,302 |
| Avg. Volume (3M) | 537,046 |
| Market Cap | 2,049,888,256 |
| Price / Sales | 464.82 |
| Price / Book | 4.82 |
| 52 Weeks Range | |
| Earnings Date | 6 Nov 2025 |
| Profit Margin | 31.01% |
| Operating Margin (TTM) | 29.97% |
| Diluted EPS (TTM) | 0.070 |
| Total Debt/Equity (MRQ) | 8.84% |
| Current Ratio (MRQ) | 16.10 |
| Operating Cash Flow (TTM) | 69.88 M |
| Levered Free Cash Flow (TTM) | 52.09 M |
| Return on Assets (TTM) | 23.07% |
| Return on Equity (TTM) | 34.38% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | Maze Therapeutics, Inc. | Bullish | - |
AIStockmoo Score
| Analyst Consensus | -1.5 |
| Insider Activity | NA |
| Price Volatility | -3.0 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | 4.0 |
| Average | -0.13 |
|
Maze Therapeutics Inc is a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small-molecule precision medicines for patients living with renal, cardiovascular and related metabolic, or CVRM, diseases, including obesity. The company is advancing a pipeline using its Compass platform, which allows the company to identify and characterize genetic variants in disease and then link those variants to the biological pathways that drive disease in specific patient groups through a process it refers to as variant functionalization. It is currently advancing two programs, MZE829 and MZE782, each of which represents a novel precision medicine-based approach for chronic kidney disease, or CKD. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| % Held by Insiders | 5.91% |
| % Held by Institutions | 92.25% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Trv Gp Iv, Llc | 30 Sep 2025 | 6,073,958 |
| A16z Capital Management, L.L.C. | 30 Sep 2025 | 1,702,225 |
| Matrix Capital Management Company, Lp | 30 Sep 2025 | 1,653,684 |
| General Catalyst Group Management, Llc | 30 Sep 2025 | 1,035,910 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 60.00 (HC Wainwright & Co., 40.85%) | Buy |
| Median | 37.00 (-13.15%) | |
| Low | 34.00 (Guggenheim, -20.19%) | Buy |
| Average | 43.17 (1.34%) | |
| Total | 6 Buy | |
| Avg. Price @ Call | 30.74 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Wells Fargo | 04 Dec 2025 | 55.00 (29.11%) | Buy | 42.60 |
| HC Wainwright & Co. | 03 Dec 2025 | 60.00 (40.85%) | Buy | 41.49 |
| 18 Sep 2025 | 50.00 (17.37%) | Buy | 23.48 | |
| Wedbush | 07 Nov 2025 | 36.00 (-15.49%) | Buy | 28.60 |
| JP Morgan | 29 Sep 2025 | 37.00 (-13.15%) | Buy | 25.20 |
| Guggenheim | 15 Sep 2025 | 34.00 (-20.19%) | Buy | 23.25 |
| BTIG | 12 Sep 2025 | 37.00 (-13.15%) | Buy | 23.30 |
| 11 Sep 2025 | 37.00 (-13.15%) | Buy | 24.80 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 06 Nov 2025 | Announcement | Maze Therapeutics to Present Additional Data Highlighting the Advancement of MZE829 and MZE782 Programs at ASN Kidney Week |
| 06 Nov 2025 | Announcement | Maze Therapeutics Reports Third Quarter 2025 Financial Results and Recent Highlights |
| 04 Nov 2025 | Announcement | Maze Therapeutics to Participate in Four Upcoming Investor Conferences |
| 06 Oct 2025 | Announcement | Maze Therapeutics Appoints Industry Veteran Hervé Hoppenot as Chairman of the Board of Directors |
| 11 Sep 2025 | Announcement | Maze Therapeutics Announces Oversubscribed $150.0 Million Private Placement |
| 11 Sep 2025 | Announcement | Maze Therapeutics Announces Positive First-in-Human Results from Phase 1 Trial of MZE782, Establishing Proof of Mechanism for a Potent, Oral SLC6A19 Inhibitor with Potential to Treat Phenylketonuria (PKU) and Chronic Kidney Disease (CKD) |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |